ReviewThe Journal of clinical and aesthetic dermatology2021
New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications.
Review in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Patients with Severe Recalcitrant Nodular Facial Acne in India: a Real-World Retrospective Study Using Electronic Medical Records.Dermatology and therapy · 2026Article
- Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations.Dermatology and therapy · 2026Review
- Association of fast foods and dairy products in acne severity and scarring: a cross-sectional study.Annals of medicine and surgery (2012) · 2026Article
- Efficacy, psychological and physical adverse effects of isotretinoin in the treatment of acne: a cross-sectional study from Syria.Scientific reports · 2025Article
- Virtual and in Vitro Screening Employing a Repurposing Approach Reveal 13-cis-Retinoic Acid is a PTP1B Inhibitor.ChemMedChem · 2024Article
- Acne among Patients Visiting Outpatient Department of Dermatology Centres.JNMA; journal of the Nepal Medical Association · 2023Article
- Oral Isotretinoin and Its Uses in Dermatology: A Review.Drug design, development and therapy · 2023Review
- Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports.The Journal of clinical and aesthetic dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isotretinoin is a widely used and effective drug in the treatment of severe, recalcitrant, nodular acne. However, its poor aqueous solubility limits oral bioavailability and requires administration with a high-fat, high-calorie meal (HF/HC) for optimal absorption; poor patient adherence may decrease effective dosing and treatment efficacy. Objective: This review covers the properties of the lidose isotretinoin and micronized isotretinoin formulations and their use in acne therapy. Method of Literature Search: PubMed was searched using the terms Results: Our review discusses pathology and approved treatment options for acne; provides mechanism of action of isotretinoin; presents clinical challenges associated with isotretinoin safety; and summarizes implications in clinical practice. Newer formulations show enhanced bioavailability in both fed and fasting states. Limitations: Few published studies of real-world use of the identified formulations were available. Conclusion: Newer drug delivery technologies can simplify isotretinoin use while maximizing bioavailability and efficacy. Based on our analysis, lidose isotretinoin and micronized isotretinoin improve oral bioavailability, pharmacological bioactivity, and increase therapeutic efficacy in patients who are unwilling or unable to consistently take the medication with an HF/HC meal. Healthcare providers should consider these formulations as tools to optimize treatment based on each patient's individual needs.
Indexed as
Identifiers
35291260PMC8903225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.